Bausch + Lomb Corporation (BLCO) Stock Price & Analysis
Bausch + Lomb Corporation (BLCO) closed at USD 17.43 on Thursday, October 22, 2026, up 1.46% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 17.43; the Oct 22, 2026 session ranged USD 17.01–17.45 on volume of 426,367 shares. Market capitalization is —, with a 52-week range of USD 14.44–18.92 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:23 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BLCO.md
Key facts (BLCO)
- Last four reported quarters (through Jun 30, 2026): revenue $5.32B, net income -$171M (-3.2% margin), free cash flow $137M (SEC filings).
- 3 of 80 tracked superinvestors hold BLCO (13F, Q2 2026): 1 new, 1 added, 0 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $1.2M; 2 not under a Rule 10b5-1 plan ($1.2M); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.53 on a 1–5 scale) (15 analysts), mean target USD 19.39 (range 16–24).
- Total return with dividends: 1Y +10.5% vs S&P 500 +14.9%; 5Y -12.8% vs S&P 500 +80.3%.
- Next earnings: 2026-10-28, EPS estimate USD 0.22, revenue estimate $1.37B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BLCO)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $3.77B | $3.77B | $4.15B | $4.79B | $5.10B | $5.32B |
| Operating income | $329M | $207M | $130M | $162M | $113M | $323M |
| Net income | $182M | $6.0M | -$260M | -$317M | -$360M | -$171M |
| EPS (diluted) | $0.52 | $0.02 | -$0.74 | -$0.90 | -$1.02 | — |
| Free cash flow | $680M | $170M | -$198M | -$59.0M | -$66.0M | $137M |
| Operating margin | 8.7% | 5.5% | 3.1% | 3.4% | 2.2% | 6.1% |
| Net margin | 4.8% | 0.2% | -6.3% | -6.6% | -7.1% | -3.2% |
| Revenue growth | +10.3% | +0.1% | +10.0% | +15.6% | +6.5% | — |
| Cash + short-term investments | $174M | $354M | $331M | $305M | $383M | — |
| Total debt | $0K | $2.44B | $4.56B | $4.78B | $5.05B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (BLCO)
P/S 1.2x · EV/EBITDA 14.9x · EV/Sales 2.0x · P/FCF 45.4x · P/B 1.0x · FCF yield 2.20% · Earnings yield -2.75% · Net debt $4.71B · EV $10.9B
Superinvestors (SEC 13F-HR, Q2 2026) (BLCO)
3 of 80 tracked investors hold BLCO. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Howard Marks | Oaktree Capital | 1.51% | $57.0M | Added +1.7% |
| Carl Icahn | Icahn Capital Management | 0.70% | $58.0M | Unchanged |
| Daniel Loeb | Third Point | 0.03% | $1.4M | New position |
Insider sales (SEC Form 4, open-market, last ~7 months) (BLCO)
0 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-10 | Munsch Frederick | SVP, Controller and CAO | 52,900 | $888K | 53.6% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-08-06…2026-08-07 | Von Eschenbach Andrew C. | Director | 18,559 | $307K | 22.6% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (BLCO)
Consensus Hold (mean 2.53 on a 1–5 scale), 15 analysts; mean target USD 19.39 (low 16, high 24).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | Barclays | Initiated | Overweight | $24 |
| 2026-09-15 | Needham | Reiterated | Hold | |
| 2026-09-09 | Leerink Partners | Initiated | Outperform | $24 |
| 2026-08-28 | HC Wainwright & Co. | Reiterated | Buy | $21 |
| 2026-08-03 | HC Wainwright & Co. | Target raised | Buy | $20 → $21 |
| 2026-07-30 | UBS | Target raised | Buy | $21 → $23 |
| 2026-07-28 | UBS | Initiated | Buy | $21 |
| 2026-07-08 | Citigroup | Target raised | Buy | $19 → $21 |
| 2026-07-06 | Evercore ISI Group | Target raised | In-Line | $16 → $17 |
Total return (dividends reinvested) (BLCO)
| 1Y (from 2025-10-23) | 5Y (from 2022-05-02) | |
|---|---|---|
| Total return | +10.5% | -12.8% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +10.5% | -3.0% |
| Volatility (annualized) | 29.3% | 38.5% |
| Max drawdown | -20.1% (Feb 2026→Jun 2026) | -46.0% (Jul 2023→May 2025) |
BLCO revenue by business segment (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Vision Care | $784.0M | 56.2% | +4.1% |
| Pharmaceuticals | $354.0M | 25.4% | +14.6% |
| Surgical | $256.0M | 18.4% | +18.5% |
| Total revenue | $1.39B | 100% | — |
BLCO revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Product sales | $1.39B | 99.6% | +9.2% |
| OTC | $497.0M | 35.7% | +3.1% |
| Devices | $270.0M | 19.4% | +4.7% |
| Branded and Other Generics | $13.0M | 0.9% | +30.0% |
| Other revenues | $5.0M | 0.4% | -16.7% |
| Other revenues | $3.0M | 0.2% | +50.0% |
| Pharmaceuticals | $1.0M | 0.1% | +0.0% |
| Total revenue | $1.39B | 100% | — |
BLCO revenue by region (fiscal year ended Dec 31, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United Statesand Puerto Rico | $2.55B | 49.9% | +5.5% |
| Other Countries | $777.0M | 15.2% | +9.1% |
| China | $358.0M | 7.0% | +0.0% |
| France | $246.0M | 4.8% | +8.4% |
| Japan | $186.0M | 3.6% | +3.3% |
| Germany | $164.0M | 3.2% | +7.9% |
| Russia | $148.0M | 2.9% | +23.3% |
| United Kingdom | $137.0M | 2.7% | +3.8% |
| Canada | $135.0M | 2.6% | +6.3% |
| Italy | $102.0M | 2.0% | +12.1% |
| Spain | $101.0M | 2.0% | +9.8% |
| Mexico | $75.0M | 1.5% | +0.0% |
| Poland | $75.0M | 1.5% | +15.4% |
| South Korea | $51.0M | 1.0% | +8.5% |
| Total revenue | $5.10B | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
BLCO suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Related party | Bausch Health Companies Inc. (BHC) | “Although all transactions with related parties will be approved by independent members of our Board of Directors that may meet in the absence of senior executive officers or non-independent directors, the ownership of BHC equity or service to BHC may create the appearance of conflicts of interest when the BHC-affiliated directors and officers are faced with decisions that could have different implications for BHC …” |
Quoted from the company's 10-K filed Feb 18, 2026.
BLCO customer concentration
In the period ended Dec 31, 2025, 2 direct customers each accounted for at least 10% (10%, 10%) of revenue, per the company's 10-K filed Feb 18, 2026. The company does not name them.
BLCO company outlook (results filed Jul 29, 2026)
- “Guidance • Revenue of $1.394 Billion • Revenue Grew 9% as Reported and 8% on a Constant Currency 1 Basis Compared to the Second Quarter of 2025 • GAAP Net Loss Attributable to Bausch + Lomb Corporation of $14 Million • Adjusted EBITDA (non-GAAP) 1 of $241 Million;”
Quoted word-for-word from the SEC 8-K results press release.
BLCO analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.22 | $0.22 | +1.5% | $1.37B | 14 |
| Next quarter (ends Dec 2026) | $0.35 | $0.35 | +1.1% | $1.49B | 14 |
| Current fiscal year (ends Dec 2026) | $0.81 | $0.80 | +0.9% | $5.49B | 14 |
| Next fiscal year (ends Dec 2027) | $1.11 | $1.07 | +4.1% | $5.82B | 14 |
Key Statistics (as of October 23, 2026 at 09:23 UTC)
| Price | USD 17.43 |
|---|---|
| Change | ▲ 1.46% (up) |
| Previous Close | USD 17.43 |
| Open | USD 17.43 |
| Day Range | USD 17.01 – 17.45 |
| 52-Week Range | USD 14.44 – 18.92 |
| Volume | 426,367 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (BLCO)
Nexqual's technical model rates BLCO "BUY" based on 4 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:23 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 54.64 (neutral) |
| vs SMA50 | Above (USD 17.14) |
| MACD | -0.04 (negative) |
Analyst Ratings (BLCO)
Wall Street analysts rate BLCO "Hold" based on 15 analysts, with a mean price target of USD 19.39 (range USD 16–24), per Nexqual as of October 23, 2026 at 09:23 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 19.39 |
| High Target | USD 24 |
| Low Target | USD 16 |
| Buy / Hold / Sell | 7 / 7 / 1 |
Earnings (BLCO)
| Next Earnings Date | 2026-10-28 |
|---|---|
| EPS Estimate | USD 0.22 |
| Revenue Estimate | $1.37B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.16 vs est 0.16 ▼ miss |
| 2026-03-31 | USD 0.08 vs est 0.05 ▲ beat |
| 2025-12-31 | USD 0.32 vs est 0.36 ▼ miss |
| 2025-09-30 | USD 0.18 vs est 0.16 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financials & Fundamentals (BLCO)
| Total Revenue | $5.32B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +9.10% |
| Gross Margin | +61.44% |
| Operating Margin | +7.75% |
| Profit Margin | -3.21% |
| ROE | -2.52% |
| Debt / Equity | 0.79 |
| Current Ratio | 1.55 |
| Total Cash | $367.00M |
| Total Debt | $5.11B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $137.00M (2.6% of revenue) |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Financial Health Score (BLCO)
Nexqual rates Bausch + Lomb Corporation's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:23 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 61%, operating 8% (last 12 months) |
| Balance Sheet | Mixed — $367M cash and investments vs $5.08B debt (Jun 2026, SEC) |
| Cash Flow | Mixed — FCF $137M (last 4 quarters to Jun 2026, SEC), slim 2.6% margin |
| Efficiency | Critical — ROE -3%, ROA 1.8% |
Ownership (BLCO)
| Insider Ownership | +87.29% |
|---|---|
| Institutional Ownership | +11.25% |
| Shares Outstanding | 357.17M |
| Float | 46.06M |
| Short % of Float | +6.48% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
Leadership (BLCO)
Bausch + Lomb Corporation is led by Luc Bonnefoy, President of Surgical, per Nexqual as of October 23, 2026 at 09:23 UTC.
| President of Surgical | Luc Bonnefoy |
|---|---|
| President of Consumer | John Ferris |
| President of Vision Care | Yang Yang |
Major Backers & Investors (BLCO)
Notable institutional backers of Bausch + Lomb Corporation include Icahn Carl C, Oaktree Capital Management LP, Shaw D.E. & Co., Inc., according to Nexqual as of October 23, 2026 at 09:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Icahn Carl C | 0.98% |
| Oaktree Capital Management LP | 0.96% |
| Shaw D.E. & Co., Inc. | 0.93% |
| Davidson Kempner Capital Management LP | 0.88% |
| Goldentree Asset Management LP | 0.74% |
| Price (T.Rowe) Associates Inc | 0.6% |
| CASPIAN CAPITAL, LP | 0.56% |
| Glenview Capital Management, Llc | 0.54% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Deutsche Bank AG | 0.96% |
Source: Nexqual, October 23, 2026 at 09:23 UTC.
From Bausch + Lomb Corporation's Latest SEC 10-K Filing (filed 2026-02-18)
Key Strengths & Strategy (as disclosed to the SEC)
- Our principal consumer eye care products include: •PreserVision® AREDS 2 a patented eye vitamin and mineral supplement that contains the exact nutrient formula recommended by the National Eye Institute for people with moderate to advanced age-related macular degeneration ("AMD") following the landmark AREDS 2 clinical study.
- MIEBO® is the first and only FDA-approved treatment for DED that directly targets tear evaporation and the addition of MIEBO® is expected to help build upon our strong portfolio of integrated eye health products. •XIPERE® (triamcinolone acetonide suprachoroidal injectable suspension) is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for suprachoroidal administration via the proprietary SCS Microinjector®.
- Food and Drug Administration (the "FDA") approval of a new drug compound ("NCE") in a New Drug Application ("NDA").
- The FDA, with one exception, is prohibited during those five years from accepting for filing a generic, or an Abbreviated New Drug Application ("ANDA"), that references the NDA.
Legal & Regulatory Risks (Item 1A, quoted)
- Changes in inventory levels or fluctuations in buying patterns by our large distributor and retail customers may adversely affect our sales and earnings and add to sales variability from quarter to quarter.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TFX | Teleflex Incorporated | USD 136.58 | ▲ 4.74% |
| MMSI | Merit Medical Systems, Inc. | USD 93.94 | ▲ 2.78% |
| STVN | Stevanato Group S.p.A. | USD 19.5 | ▲ 3.61% |
| MMED | MiniMed Group, Inc. | USD 18.29 | ▲ 2.75% |
| ATR | AptarGroup, Inc. | USD 128.1 | ▲ 1.97% |
| ICUI | ICU Medical, Inc. | USD 168.33 | ▲ 4.66% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:23 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt